Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T88304
|
||||
Former ID |
TTDNC00597
|
||||
Target Name |
DNMT1
|
||||
Gene Name |
DNMT1
|
||||
Synonyms |
CXXCtype zinc finger protein 9; DNA (cytosine5)methyltransferase 1; DNA MTase HsaI; DNA methyltransferase HsaI; Dnmt1; M.HsaI; MCMT; DNMT1
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Acute myeloid leukemia [ICD9: 205; ICD10: C92.0] | ||||
Acute myeloid leukemia; Myelodysplastic syndrome [ICD9:205, 238.7; ICD10: C92.0, D46] | |||||
Cancer [ICD9: 140-229; ICD10: C00-C96] | |||||
Glioblastoma multiforme [ICD9: 191; ICD10: C71] | |||||
Late-stage solid tumors [ICD9: 140-199, 210-229; ICD10: C00-C75, C7A, C7B, D10-D36, D3A] | |||||
Myelodysplastic syndrome [ICD9: 238.7; ICD10: D46] | |||||
Non-small cell lung cancer [ICD10: C33-C34] | |||||
Soft tissue sarcoma [ICD9: 171; ICD10: C00-D49] | |||||
Function |
Methylates CpG residues. Preferentially methylates hemimethylated DNA. Associates with DNA replication sites in S phase maintaining the methylation pattern in the newly synthesized strand, that is essential for epigenetic inheritance. Associates with chromatin during G2 and M phases to maintain DNA methylation independently of replication. It is responsible for maintaining methylation patterns established in development. DNA methylationis coordinated with methylation of histones. Mediates transcriptional repression by direct binding to HDAC2. In association with DNMT3B and via the recruitment of CTCFL/BORIS, involved in activation of BAG1 gene expression by modulating dimethylation of promoter histone H3 at H3K4 and H3K9.
|
||||
BioChemical Class |
Methyltransferase superfamily
|
||||
UniProt ID | |||||
EC Number |
EC 2.1.1.37
|
||||
Sequence |
MPARTAPARVPTLAVPAISLPDDVRRRLKDLERDSLTEKECVKEKLNLLHEFLQTEIKNQ
LCDLETKLRKEELSEEGYLAKVKSLLNKDLSLENGAHAYNREVNGRLENGNQARSEARRV GMADANSPPKPLSKPRTPRRSKSDGEAKPEPSPSPRITRKSTRQTTITSHFAKGPAKRKP QEESERAKSDESIKEEDKDQDEKRRRVTSRERVARPLPAEEPERAKSGTRTEKEEERDEK EEKRLRSQTKEPTPKQKLKEEPDREARAGVQADEDEDGDEKDEKKHRSQPKDLAAKRRPE EKEPEKVNPQISDEKDEDEKEEKRRKTTPKEPTEKKMARAKTVMNSKTHPPKCIQCGQYL DDPDLKYGQHPPDAVDEPQMLTNEKLSIFDANESGFESYEALPQHKLTCFSVYCKHGHLC PIDTGLIEKNIELFFSGSAKPIYDDDPSLEGGVNGKNLGPINEWWITGFDGGEKALIGFS TSFAEYILMDPSPEYAPIFGLMQEKIYISKIVVEFLQSNSDSTYEDLINKIETTVPPSGL NLNRFTEDSLLRHAQFVVEQVESYDEAGDSDEQPIFLTPCMRDLIKLAGVTLGQRRAQAR RQTIRHSTREKDRGPTKATTTKLVYQIFDTFFAEQIEKDDREDKENAFKRRRCGVCEVCQ QPECGKCKACKDMVKFGGSGRSKQACQERRCPNMAMKEADDDEEVDDNIPEMPSPKKMHQ GKKKKQNKNRISWVGEAVKTDGKKSYYKKVCIDAETLEVGDCVSVIPDDSSKPLYLARVT ALWEDSSNGQMFHAHWFCAGTDTVLGATSDPLELFLVDECEDMQLSYIHSKVKVIYKAPS ENWAMEGGMDPESLLEGDDGKTYFYQLWYDQDYARFESPPKTQPTEDNKFKFCVSCARLA EMRQKEIPRVLEQLEDLDSRVLYYSATKNGILYRVGDGVYLPPEAFTFNIKLSSPVKRPR KEPVDEDLYPEHYRKYSDYIKGSNLDAPEPYRIGRIKEIFCPKKSNGRPNETDIKIRVNK FYRPENTHKSTPASYHADINLLYWSDEEAVVDFKAVQGRCTVEYGEDLPECVQVYSMGGP NRFYFLEAYNAKSKSFEDPPNHARSPGNKGKGKGKGKGKPKSQACEPSEPEIEIKLPKLR TLDVFSGCGGLSEGFHQAGISDTLWAIEMWDPAAQAFRLNNPGSTVFTEDCNILLKLVMA GETTNSRGQRLPQKGDVEMLCGGPPCQGFSGMNRFNSRTYSKFKNSLVVSFLSYCDYYRP RFFLLENVRNFVSFKRSMVLKLTLRCLVRMGYQCTFGVLQAGQYGVAQTRRRAIILAAAP GEKLPLFPEPLHVFAPRACQLSVVVDDKKFVSNITRLSSGPFRTITVRDTMSDLPEVRNG ASALEISYNGEPQSWFQRQLRGAQYQPILRDHICKDMSALVAARMRHIPLAPGSDWRDLP NIEVRLSDGTMARKLRYTHHDRKNGRSSSGALRGVCSCVEAGKACDPAARQFNTLIPWCL PHTGNRHNHWAGLYGRLEWDGFFSTTVTNPEPMGKQGRVLHPEQHRVVSVRECARSQGFP DTYRLFGNILDKHRQVGNAVPPPLAKAIGLEIKLCMLAKARESASAKIKEEEAAKD |
||||
Drugs and Mode of Action | |||||
Drug(s) | CC-486 | Drug Info | Phase 3 | Myelodysplastic syndrome | [549703] |
S-110 | Drug Info | Phase 3 | Acute myeloid leukemia | [525074] | |
SGI110 | Drug Info | Phase 3 | Acute myeloid leukemia; Myelodysplastic syndrome | [525074] | |
Antroquinonol | Drug Info | Phase 2 | Non-small cell lung cancer | [524616] | |
Palifosfamide | Drug Info | Phase 2 | Soft tissue sarcoma | [524236] | |
Oral azacitidine | Drug Info | Phase 1 | Myelodysplastic syndrome | [524889], [531480] | |
RX-3117 | Drug Info | Phase 1 | Late-stage solid tumors | [524590] | |
Inhibitor | Antroquinonol | Drug Info | [532758] | ||
CC-486 | Drug Info | [533326] | |||
CP-4200 | Drug Info | [543657] | |||
Oral azacitidine | Drug Info | [528903] | |||
Palifosfamide | Drug Info | [531674] | |||
RX-3117 | Drug Info | [532483] | |||
S-110 | Drug Info | [530893] | |||
XB-05 | Drug Info | [543657] | |||
Modulator | PMX-700 | Drug Info | [543657] | ||
SGI110 | Drug Info | [533185] | |||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Cysteine and methionine metabolism | ||||
Metabolic pathways | |||||
MicroRNAs in cancer | |||||
Pathway Interaction Database | Regulation of retinoblastoma protein | ||||
PathWhiz Pathway | Methionine Metabolism | ||||
Reactome | PRC2 methylates histones and DNA | ||||
NoRC negatively regulates rRNA expression | |||||
DNA methylation | |||||
WikiPathways | Trans-sulfuration and one carbon metabolism | ||||
Retinoblastoma (RB) in Cancer | |||||
One Carbon Metabolism | |||||
Trans-sulfuration pathway | |||||
References | |||||
Ref 524236 | ClinicalTrials.gov (NCT01808534) Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors. U.S. National Institutes of Health. | ||||
Ref 524590 | ClinicalTrials.gov (NCT02030067) Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies. U.S. National Institutes of Health. | ||||
Ref 524616 | ClinicalTrials.gov (NCT02047344) Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC. U.S. National Institutes of Health. | ||||
Ref 524889 | ClinicalTrials.gov (NCT02223052) CC-486 (Oral Azacitidine) Bioequivalence Study in Patients With Solid Tumor or Hematologic Malignancies. U.S. National Institutes of Health. | ||||
Ref 525074 | ClinicalTrials.gov (NCT02348489) SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction. U.S. National Institutes of Health. | ||||
Ref 528903 | 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther. 2007 Jun;6(6):1718-27. | ||||
Ref 530893 | S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010 May;9(5):1443-50. | ||||
Ref 531674 | Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012 Feb;23(2):173-84. | ||||
Ref 532483 | Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Invest New Drugs. 2013 Dec;31(6):1444-57. | ||||
Ref 532758 | Antroquinonol D, isolated from Antrodia camphorata, with DNA demethylation and anticancer potential. J Agric Food Chem. 2014 Jun 18;62(24):5625-35. | ||||
Ref 533185 | Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10(3):237-46. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.